The Protocol Review and Monitoring System (PRMS), administered by Winship?s Clinical and Translational Review Committee (CTRC), is responsible for the review and approval of all cancer clinical trials proposed by Winship members for scientific quality and merit. The CTRC is charged with the responsibility to prioritize, monitor, and terminate clinical trials based on ongoing scientific validity, feasibility, overall progress, and patient accrual. CTRC?s overarching goal is to support and facilitate the conduct of Winship?s clinical cancer research efforts. To fulfil this goal, CTRC addresses the following set of objectives using clearly-defined criteria and mechanisms to: (1) review new clinical research proposals for scientific rationale, appropriate design, and feasibility; (2) prioritize clinical research proposals using uniform and objective metrics in consultation with Winship?s cancer disease-site working groups and with Winship?s research programs to ensure alignment with Winship?s overall strategic objectives; (3) review and monitor the progress of active clinical studies for accrual and scientific validity, and to terminate protocols which are not meeting accrual targets and/or where new scientific evidence renders the study irrelevant; (4) determine and assign level of potential risk to patients enrolled on study that will inform the rigor and frequency of review by Winship?s Data Safety Monitoring Committee (DSMC); and (5) provide a platform for educating the next generation of clinical researchers on the best practices in the design and conduct of cancer clinical trials. The CTRC functions as a distinct, independent body from the Winship Clinical Trials Office (CTO) and the DSMC. Significant changes instituted to enhance the function of the CTRC in response to suggestions emanating from the last CCSG competitive renewal include: (1) enactment of review guidelines to assess the ability of new studies to meet accrual targets, with special attention to potential eligibility conflict with ongoing clinical trials; (2) adding a requirement that new study proposals address scientific questions relevant to Winship?s overall mission and objectives of its research programs; (3) adding a requirement for institutional (investigator-initiated) proposals to undergo biostatistics review prior to submission for CTRC review and to include a co-investigator from Winship?s Biostatistics and Bioinformatics Shared Resource (BBISR); (4) requiring a risk level determination at the time of scientific review for all treatment trials; (5) instituting a regular biennial survey of Winship members to obtain feedback on CTRC function and value added to Winship?s clinical research activities; and (6) recognizing outstanding CTRC members (excluding co-chairs) based on specific metrics including meeting attendance and protocol review.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
United States
Zip Code
Goldstein, Jordan S; Nastoupil, Loretta J; Han, Xuesong et al. (2018) Disparities in survival by insurance status in follicular lymphoma. Blood 132:1159-1166
Richardson, Alessandra M; Havel, Lauren S; Koyen, Allyson E et al. (2018) Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion. Clin Cancer Res 24:420-432
Jin, Lingtao; Chun, Jaemoo; Pan, Chaoyun et al. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell 34:315-330.e7
Guidot, Daniel M; Switchenko, Jeffrey M; Nastoupil, Loretta J et al. (2018) Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk Lymphoma 59:888-895
Chowdhary, Mudit; Okwan-Duodu, Derick; Switchenko, Jeffrey M et al. (2018) Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. J Neurooncol 136:289-298
Chen, Zhengjia; Zheng, Youyun; Wang, Zhibo et al. (2018) Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs. Contemp Clin Trials Commun 12:145-153
Halani, Sameer H; Yousefi, Safoora; Vega, Jose Velazquez et al. (2018) Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. NPJ Precis Oncol 2:24
Ferris, Matthew J; Liu, Yuan; Ao, Jingning et al. (2018) The addition of chemotherapy in the definitive management of high risk prostate cancer. Urol Oncol 36:475-487
Halicek, Martin; Little, James V; Wang, Xu et al. (2018) Deformable Registration of Histological Cancer Margins to Gross Hyperspectral Images using Demons. Proc SPIE Int Soc Opt Eng 10581:
Cassidy, Richard J; Switchenko, Jeffrey M; El-Deiry, Mark W et al. (2018) Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas. Laryngoscope :

Showing the most recent 10 out of 331 publications